Hepatocellular Carcinoma
Conditions
Interventions
Experimental group:IPM001 injection
Sponsors
Huashan Hospital Affiliated to Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Understand and voluntarily sign the informed consent; 2. Aged 18 to 75 years, male or female; 3. Patients with primary hepatocellular carcinoma; 4. According to the National Health and Family Planning Commission of the People's Republic of China for the diagnosis and treatment of primary liver cancer (2017 edition) clinical staging of liver cancer (see Appendix 1), patients with stage Ia ~ IIIa; 5. Child-Pugh score =1 peptide library Neoantigen or >=2 peptide library aeTSA; 7. ECOG PS score is 0~2 points; 8. No major organ dysfunction (laboratory examination): (1) White blood cell count >= 3.0 x 10^9/L; (2) Neutrophils >= 1.5 x 10^9/L; (3) Hemoglobin >= 85g/L; (4) Platelet count >= 5 x 10^10/L; (5) Total bilirubin = 3.0 g/dL (30 g/L); (8) Serum creatinine 50 kg, female > 45 kg; 10. No obvious genetic disease; 11. Expected survival >= 6 months.
Exclusion criteria
Exclusion criteria: 1. Suffer from lymphoma or leukemia or MDS (myelodysplastic syndrome), etc.; 2. Woman be pregnant or lactating; 3. Suffer from mental or neurological diseases that are resistant to control; 4. The investigator judges that it is not suitable to participate in this clinical research (such as poor compliance, etc.) 5. Patients infected with human immunodeficiency virus (commonly known as AIDS) or Treponema pallidum (commonly known as syphilis); 6. Patients with a history of other malignant tumors in the past 5 years; 7. Organ transplantation or Myelosuppression; 8. History of drug abuse or alcohol abuse.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Quality of Life; | — |
Countries
China
Contacts
Public ContactZhang Hao
Huashan Hospital Affiliated to Fudan University
Outcome results
None listed